For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Prevena | Subjects will receive PREVENA after surgery. Prevena: Closed Incision Negative Pressure Therapy (bandage over the incision sealed with negative pressure of a vacuum) to be placed on after surgery for 7 days. Prevenaâ„¢, by KCI, is currently being used selectively in high-risk patients and a FDA-approved device. | 0 | None | 1 | 60 | 5 | 60 | View |
| Aquacel | Subjects will receive AQUACEL Ag after surgery. Aquacel: Water resistant, silver-impregnated, antimicrobial hydrofiber dressing that is placed on after surgery for 7 days. AQUACEL® Ag, by Convatec, is currently the standard of care for postoperative wound dressing and a FDA-approved device. | 0 | None | 0 | 60 | 11 | 60 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Acute periprosthetic joint infection | SYSTEMATIC_ASSESSMENT | Surgical and medical procedures | None | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Surgical site complications | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |